Harringer Wolfgang, Haverich Axel
Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30623
World J Surg. 2002 Feb;26(2):218-25. doi: 10.1007/s00268-001-0209-y. Epub 2001 Dec 24.
Standards and new developments of thoracic organ transplantation are reviewed with particular focus on current treatment strategies, alternatives to transplantation, and xenotransplantation. The current indications for heart, single and bilateral sequential lung, and heart-lung transplantation as well as the technical aspects of each procedure are presented. Criteria for transplant recipients and absolute and relative contraindications are pointed out. Criteria for donor selection are also reviewed. The results of single, double-sequential, and heart-lung transplantation over the past 10 years as reported by the International Society for Heart and Lung Transplantation Database are stated. In addition, the experience of the lung and heart-lung transplantation program at the Hannover Medical School is reviewed, including the current immunosuppression regimens. This experience includes 1075 heart,heart-lung, and lung transplantations since 1983. The 1- and 5-year actuarial survival rates for heart transplant recipients are 81% and 70%, for heart-lung recipients 76% and 61%, and for single and double lung transplant recipients 77% and 59%, respectively. During the past decade there has been continuous improvement in the results of heart, lung, and heart-lung transplantation. Alternatives to thoracic organ transplantation, living-related lobar transplantation, new antirejection agents, and xenograft transplantation are areas for continuing and future investigation.
本文综述了胸器官移植的标准和新进展,特别关注当前的治疗策略、移植替代方案和异种移植。介绍了心脏、单肺和双肺序贯移植以及心肺移植的当前适应症,以及每种手术的技术要点。指出了移植受者的标准以及绝对和相对禁忌症。还综述了供体选择标准。阐述了国际心肺移植协会数据库报告的过去10年单肺、双肺序贯移植和心肺移植的结果。此外,还回顾了汉诺威医学院肺和心肺移植项目的经验,包括当前的免疫抑制方案。该经验涵盖了自1983年以来的1075例心脏、心肺和肺移植。心脏移植受者的1年和5年精算生存率分别为81%和70%,心肺移植受者为76%和61%,单肺和双肺移植受者分别为77%和59%。在过去十年中,心脏、肺和心肺移植的结果持续改善。胸器官移植的替代方案、亲属活体肺叶移植、新型抗排斥药物和异种移植是持续和未来研究的领域。